FDA Approves Second Generic Mifepristone, Igniting Political Firestorm
Meta Description: The FDA approved a second generic version of the abortion pill mifepristone, prompting immediate backlash from anti-abortion groups and raising questions about political influence within the agency.
WASHINGTON – The Food and Drug Administration (FDA) has approved a second generic version of mifepristone, a medication used to terminate pregnancies through 10 weeks, a move swiftly met with condemnation from opponents of abortion and Republican lawmakers. Drugmaker Evita Solutions announced the approval.
The approval has triggered a political backlash, with some alleging political interference at the FDA. Senator Josh Hawley (R-MO) stated heS lost confidence in FDA leadership.
Did you know? The FDA states it has limited discretion in approving generic drugs, requiring only bioequivalence to the original.
Pro tip: Generic drug approval typically follows patent expiration, focusing on ingredient and formulation matching.
Reader question: Will this change access? The approval isn’t expected to drastically alter access, but remains limited by state abortion laws.
The FDA initially approved mifepristone in 2000. Access expanded under the Biden administration to include mail-order prescriptions, which opponents challenge.
Evita Solutions submitted its application four years ago and plans to launch the drug in January.The drug is often used with misoprostol, accounting for two-thirds of U.S. abortions.
Restrictions on mifepristone are not supported by major medical societies like the American Medical Association and are subject to ongoing legal challenges.
